|
|
|
| To date, none of the products available for use inside the body have found widespread
acceptance among surgeons, for reasons ranging from their lack of performance in terms
of adhesiveness, flexibility, and resorption rate. Conventional adhesive matrix also presents
complexity of use,or concerns about the perceived benefit to risk. MAPTrix¢â technology
will address these unmet needs. |
|
In vivo model, MAP composition demonstrated successful bonding the outer
surfaces of skin together without apparent scar. In addition, the initial in vivo
evaluation highlighted the biocompatible benefit of mussel adhesive protein with
so rarely producing allergic reactions or necrosis inside the body when placed
in the uterus.
This result indicates the use as an adjunct to hemostasis in surgery. Further in vivo
evaluation of MAP composition for several applications is ongoing to go to preclinica
l study in mid 2008.
|
 |
|
Utilizing the biocompatibility and strong adhesive strength of MAP without the risks associated
with use of blood-derived products and fast setting times as cyanoacrylates, the Company¡¯s
second goal is to develop surgical adhesives and sealants that are easy for the surgeon to
use with long shelf time. The Company believe MAPTrix¢â technology allows to design and
develop resorption rate control of MAP matrix in conjunction with the progression of wound healing.
|
|
